Aurora Spine Corporation (ASG:CA) Q3 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call presents a mixed picture: slight improvement in gross margins and a strong October sales performance, but significant net loss and unclear guidance on repeatability of sales records. The Q&A reveals potential growth from new products but lacks clarity on financial impacts. The market cap suggests moderate sensitivity to these factors, resulting in a neutral outlook.

Key Financial Performance

Total Revenues $4.43 million, a decrease of 7.1% year-over-year from $4.77 million. The decrease was due to a transition from third-party lumbar screws to the Osteo Onyx lumbar product, with lumbar screw sales decreasing 30% from Q1 as the company worked with facilities and doctors to complete the transition.

Gross Margins 60.9% for the third quarter, a slight improvement from 60.5% in the third quarter of 2024. The improvement is attributed to selling more proprietary products and moving to direct sales.

Operating Expenses $2.81 million in the third quarter of 2025, flat compared to the third quarter of 2024 but down from $3 million in the second quarter of 2025. The decrease was due to tight expense controls, including lower G&A expenses and consulting fees, which offset increases in marketing expenses.

EBITDAC $165,000 for the third quarter of 2025, compared to $142,000 in the second quarter of 2025 and $308,000 in the third quarter of 2024. The year-over-year decrease was due to lower revenue levels.

Net Loss $842,000 for the third quarter of 2025, compared to $199,000 in the second quarter of 2025 and net income of $71,000 in the third quarter of 2024. The increase in net loss was due to lower revenue levels.

Cash Balance Nearly $700,000 at the end of the third quarter of 2025. Accounts receivables were elevated but manageable, with most receivables being 30 days or less. The company is working on improving cash collections.

You have reached the limit Upgrade to access full content

Get started

Operating Highlights

Hydra ARO: Launched in Q3 2025, with initial surgeries commenced and positive feedback received. Plans to convert to disposable kits by 2026.

DEXA-L: Launched in late Q3 2025 as part of the DEXA Technology Platform, targeting bone density-matched implants for lumbar spine issues.

SiLO platform: Generated over $2 million in Q3 2025 revenue, with continued market traction and new publications supporting its efficacy.

Sales team expansion: Currently 12 sales directors, with plans to add more in 2026. Partnering with a major university in a key market.

Biologics division: Officially launched with products like OSTEO GRAFT and TURBO FUSE.

Revenue: Q3 2025 revenue was $4.43 million, a 7.1% decrease from Q3 2024 due to transition in lumbar product offerings.

Gross margins: Improved slightly to 60.9% in Q3 2025 from 60.5% in Q3 2024, driven by proprietary product sales and direct sales.

Operating expenses: Totaled $2.81 million in Q3 2025, flat year-over-year but reduced sequentially due to tight expense controls.

Minimally invasive procedures: Focus on proprietary products like Hydra ARO and DEXA-L to capitalize on the trend towards minimally invasive spine health solutions.

You have reached the limit Upgrade to access full content

Get started

Risk or Challenges

Revenue Decline: Total revenues for the third quarter of 2025 decreased by 7.1% compared to the same quarter a year ago, primarily due to the transition from third-party lumbar screws to the Osteo Onyx lumbar product. This transition caused a 30% decrease in lumbar screw sales from Q1.

Net Loss: The company reported a net loss of $842,000 for the third quarter of 2025, compared to a net income of $71,000 in the same quarter a year ago. This reflects a significant financial challenge.

Accounts Receivable Management: Accounts receivables are elevated relative to prior quarters, which could impact cash flow. The company is working on improving the collection process, but this remains a risk.

Product Transition Challenges: The transition to new proprietary products, such as the Hydra ARO and DEXA-L, requires significant effort in educating medical professionals and building sales momentum. This could delay revenue realization.

Trademark Issue: The Hydra ARO product faced a trademark issue, requiring a name change from A.E.R.O. to ARO. While resolved, such issues can disrupt product launches and marketing efforts.

Market Penetration and Education: The company is in the early stages of penetrating the minimally invasive spine health market. Significant resources are needed for training, education, and market awareness, which could strain operational capacity.

Economic Dependency on New Products: The company’s growth heavily depends on the success of newly launched products like Hydra ARO and DEXA-L. Any delays or underperformance in these products could adversely impact financial performance.

Cash Flow Constraints: The company ended the quarter with $700,000 in cash, which may limit its ability to scale operations or invest in growth initiatives.

You have reached the limit Upgrade to access full content

Get started

Guidance & Outlook

Hydra ARO Product Development and Sales: Aurora Spine is preparing for the commercial launch of the FDA-cleared Hydra ARO facet pain device. Initial surgeries have commenced, and positive feedback has been received. Minor modifications are being made ahead of the next inventory order. The company plans to expand the number of kits in the field and aims to transition the product to a disposable kit by 2026.

DEXA-L Product Launch: The DEXA-L Anterior Lumbar Fusion system was officially launched in late Q3 2025. It is part of the patented DEXA Technology Platform, designed to address subsidence issues in the lumbar spine. Aurora Spine anticipates this product will be a key growth catalyst, targeting the large market of patients over 50 with low bone mass.

SiLO Platform Growth: The SiLO platform, including SiLO allograft and fixation systems, continues to gain traction. Aurora expects the SI joint market to expand, with SiLO products gaining more market share and contributing to revenue growth.

Sales Team Expansion: Aurora Spine plans to expand its sales team, currently at 12 directors, by adding multiple new members in 2026. The team is focused on neuro ortho customers and the interventional spine market.

Biologics Division Launch: Aurora has launched its Biologics division, including OSTEO GRAFT and TURBO FUSE products, which are expected to contribute to future growth.

Revenue and Market Penetration Goals: The company aims to enhance revenue growth through commercialization efforts, training sessions, industry conferences, and clinical data updates. Aurora is focused on penetrating minimally invasive spine health markets further in 2025 and beyond.

You have reached the limit Upgrade to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit Upgrade to access full content

Get started

Key Q&A

Q:What contributed to the increase in October sales and what set it apart from other months in the quarter?

A:The increase in October sales was attributed to the new Hydra ARO and DEXA-L products being released into the marketplace. Additionally, approvals in different locations contributed to the growth. Despite a slow start to Q3, the company closed strong and achieved an all-time record in October.

Q:Is the record sales performance in October repeatable on a monthly basis moving forward?

A:Management believes they have reached a new plateau of sales per day in growth. However, October had more sales days due to being a long month, which contributed to the record performance. They also noted that they have consistently maintained monthly sales above $1.4 million this year, aiming for an average of over $1.5 million.

Q:What is the current status of the rollout of DEXA-L and ARO, and what can be expected in the coming months?

A:For DEXA-L, the company is limited by the number of sets available but has launched with multiple physicians who are seeing great outcomes. More kits will be added next year. For ARO, about half a dozen physicians have been launched, with dozens more being onboarded through training and other events, indicating significant growth potential in the current quarter.

Q:How do you see the rollout of ARO progressing over the next three quarters?

A:The rollout of ARO is expected to follow a similar pattern to the SiLO TFX launch, starting with initial trainings, leading to physician adoption and patient offerings. Clinical research will be conducted to demonstrate the product's success and outcomes, which will help in gaining access to more physicians.

Q:What is the update on the transition to the lumbar screw system?

A:The company transitioned away from a third-party lumbar screw system and is now almost entirely using Aurora products, including Hydra Osteo Onyx. The transition was made to better align with the company's DEXA messaging and to improve product performance. The new system has received positive feedback and offers features like roughened surface technology for better bone integration.

Q:What is the early response to the DEXA-L launch?

A:The early response to DEXA-L has been very positive, with physicians appreciating the porous nature of the implant and its tooling. Early outcomes have been fantastic, and the company plans to add more DEXA-L trays in 2026 to expand its customer base.

Q:Can DEXA-L make a significant financial contribution in Q4?

A:Management believes that more kits will be needed to reach significant milestones like $0.5 million in Q4. However, the product is expected to have a financial impact as new customers adopt it, with some doctors performing 10 or more surgeries per month.

Q:Is there potential for DEXA-L users to adopt other products like DEXA-C?

A:Yes, there is potential for DEXA-L users to adopt other products like DEXA-C, especially as the company resolves issues like the APOLLO Plate failure and introduces a third-party cervical plate to support DEXA-C growth.

Q:What is the status of the APOLLO Plate redesign?

A:The company is currently using a third-party cervical plate while addressing the issues with the APOLLO Plate. They expect DEXA-C to grow in Q4 and into 2026 as they stabilize their product offerings.

Q:Review of Unclear Management Responses

A:Management avoided directly answering whether the record sales performance in October is fully repeatable on a monthly basis, citing factors like the long month and new product excitement. Additionally, they did not provide specific details on the number of doctors using DEXA-L or ARO, or the exact financial impact expected from these products in the near term.

You have reached the limit Upgrade to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

IRON Transcript

Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript

Neutral12-7

Disc Medicine, Inc. (IRON) Presents at Jefferies London Healthcare Conference 2025 Transcript

Neutral11-19

Aurora Spine Corporation (ASG:CA) Q3 2025 Earnings Call Transcript

Unknown11-18

Disc Medicine, Inc. (IRON) Presents at Stifel 2025 Healthcare Conference Transcript

Neutral11-18

IRON Report

Disc Medicine, Inc. 10-Q

10-Q

2025-08-07

Disc Medicine, Inc. 10-Q

10-Q

2024-05-09

Disc Medicine, Inc. 10-K

10-K

2024-03-21

Disc Medicine, Inc. 10-Q

10-Q

2023-11-09

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.